Analysis of Global Hepatitis E Vaccine Development Status
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".
Deadline for manuscript submissions: closed (11 September 2022) | Viewed by 450
Special Issue Editors
Interests: hepatitis; clinical virology; One Health; zoonoses
Interests: hepatitis; zoonoses; One Health; clinical virology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatitis E is a liver disease caused by the hepatitis E virus (HEV). In the vast majority of people, HEV infection results in a self-limited, acute illness. However, acute infection can become chronic in rare cases, primarily in people who have received solid-organ transplants. The human body is generally susceptible to HEV, and people of all ages can be infected. HEV is unique in that it has a different clinical and epidemiologic profile depending on where the infection is acquired. This can be attributed largely to the viral genotypes circulating in different parts of the world. Vaccination is the most direct and effective means of individual protection.
At present, there are few products in the pipeline of hepatitis E vaccine development, and research is mainly focused on recombinant protein vaccines and DNA vaccines. This Special Issue aims to gather works addressing all hepatitis E vaccine development information. This Special Issue will welcome all kinds of articles, e.g., reviews, short reports, hypotheses, research articles, opinions, and comments, on all hepatitis E vaccines.
Prof. Dr. María-Teresa Pérez-Gracia
Dr. Antonio Rivero-Juárez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
